Search Results

• • 403 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Transcription factor activity profile of acute rejection after kidney transplantation

  Authors:Weiguo Sui, Hua Lin, Yong Dai, Jiejing Chen, and He HuangFrom:Saudi Journal of Kidney Diseases and Transplantation (Vol. 24, Issue 3) Peer-Reviewed

  May-June 20132,721 words Clinical report 1410LByline: Weiguo. Sui, Hua. Lin, Yong. Dai, Jiejing. Chen, He. Huang Transcription factors (TFs) play a central role in regulating gene expression and in providing an interconnecting regulatory between related pathway...

• Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I

  From:Molecular Diagnosis & Therapy (Vol. 14, Issue 4) Peer-Reviewed

  July-August 2010461 words Report 1320LThe calcineurin inhibitors ciclosporin (cyclosporine) and tacrolimus are immunosuppressant drugs used for the prevention of organ rejection following transplantation. Both agents are metabolic substrates for cytochrome...

• Blood test may detect heart transplant rejection

  From:AORN Journal (Vol. 83, Issue 2) Peer-Reviewed

  Feb. 2006151 words Brief article 1780LA blood test may detect whether a patient who received a heart transplant is rejecting their heart, according to a Dec 15, 2005, news release from New York-Presbyterian Hospital A gene-expression test that provides a...

• Myocardial Gene Expression Profiling to Predict and Identify Cardiac Allograft Acute Cellular Rejection: The GET-Study

  Authors:Diane Bodez, Hakim Hocini, Nicolas Tchitchek, Pascaline Tisserand, Nicole Benhaiem, Caroline Barau, et al.From:PLoS ONE (Vol. 11, Issue 11) Peer-Reviewed

  Nov. 29, 20165,413 words Report 1530LAims Serial invasive endomyocardial biopsies (EMB) remain the gold standard for acute cellular rejection (ACR) diagnosis. However histological grading has several limitations. We aimed to explore the value of...

• Biomarkers to detect rejection after kidney transplantation

  Authors:Vikas R. Dharnidharka and Andrew MaloneFrom:Pediatric Nephrology (Vol. 33, Issue 7) Peer-Reviewed

  July 20188,544 words Report 1460LDetecting acute rejection in kidney transplantation has been traditionally done using histological analysis of invasive allograft biopsies, but this method carries a risk and is not perfect. Transplant professionals...

• Outcomes of paediatric kidney transplant recipients using the updated 2013/2017 Banff histopathological classification for antibody-mediated rejection.

  Authors:Evgenia Preka, Thivya Sekar, Sergio C Lopez Garcia, Olivia Shaw, Nicos Kessaris, Nizam Mamode, et al.From:Pediatric Nephrology (Vol. 36, Issue 8) Peer-Reviewed

  Aug. 20216,924 words Report 1600LBackground After the major changes with regard to acute and chronic ABMR in the Banff classification initiated in 2013, there has been an improvement in diagnosing antibody-mediated rejection (ABMR) in adult studies...

• Regulating rejection with cell therapy: regulatory T cells may prevent acute and chronic rejection of organ transplants

  Authors:Mohamed H. Sayegh and Howard L. WeinerFrom:Nature Biotechnology (Vol. 26, Issue 2) Peer-Reviewed

  Feb. 2008952 words Article 1570LTransplantation is one of the strongest challenges to the immune system. Although organ transplantation across histocompatibility barriers can be successful, lifelong administration of immunosuppressive drugs is often...

• Everolimus with low-dose cyclosporine in de novo renal transplant recipients: A single center Indian experience

  Authors:Sailaja Kesiraju, Uma Rao, Purna Paritala, V. Reddy, and S. SahariahFrom:Saudi Journal of Kidney Diseases and Transplantation (Vol. 26, Issue 6) Peer-Reviewed

  November-December 20152,833 words Letter to the editor... 1620LByline: Sailaja. Kesiraju, Uma. Rao, Purna. Paritala, V. Reddy, S. Sahariah To the Editor, Current immunosuppressive drug regimens have appreciably improved short-term outcomes following renal transplantation....

• Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates

  Authors:Tim A. Weaver, Ali H. Charafeddine, Avinash Agarwal, Alexandra P. Turner, Maria Russell, Frank V. Leopardi, et al.From:Nature Medicine (Vol. 15, Issue 7) Peer-Reviewed

  July 20091,971 words Report 1630LMemory T cells promote allograft rejection particularly in co-stimulation blockade-based immunosuppressive regimens. Here we show that the CD2-specific fusion protein alefacept (lymphocyte function-associated...

• Lung retransplantation: all for one or one for all? (editorials)

  Author:Robert M. KotloffFrom:Chest (Vol. 123, Issue 6) Peer-Reviewed

  June 20031,182 words Article Long-term preservation of allograft function remains an elusive goal following lung transplantation. Despite current immunosuppressive strategies, bronchiolitis obliterans syndrome (BOS), a disorder characterized by...

• Hyperacute rejection following lung transplantation

  Authors:Adanni E. Frost, Cory T. Jammal, and Philip T. CagleFrom:Chest (Vol. 110, Issue 2) Peer-Reviewed

  Aug. 19962,068 words Article Although hyperacute rejection has been clinically and pathologically fully described in recipients of other solid organ transplants, to our knowledge, there have been no previous fully documented cases in recipients of...

• Surveillance bronchoscopy in lung transplant recipients

  Authors:David S. Kukafka, Gerald M. O'Brien, Satoshi Furukawa, and Gerald J. CrinerFrom:Chest (Vol. 111, Issue 2) Peer-Reviewed

  Feb. 19973,512 words Article Study objectives: To establish whether a consensus exists among active transplant centers regarding the use and interpretation of information obtained by surveillance bronchoscopic lung biopsy (SBLB). Design: Prospective...

• Peak serum AST is a better predictor of acute liver graft injury after liver transplantation when adjusted for donor/recipient bsa size mismatch (ASTi)

  Authors:Kyota Fukazawa, Seigo Nishida, and Ernesto A. Pretto, Jr.From:Journal of TransplantationPeer-Reviewed

  Annual 20143,852 words Report 1550LBackground. Despite the marked advances in the perioperative management of the liver transplant recipient, an assessment of clinically significant graft injury following preservation and reperfusion remains difficult....

• Expression of VE-Cadherin in peritubular endothelial cells during acute rejection after human renal transplantation

  Authors:Ana Roussoulieres, Brigitte McGregor, Lara Chalabreysse, Catherine Cerutti, Jeanne-Luce Garnier, Pascale Boissonnat, et al.From:Journal of Biomedicine and BiotechnologyPeer-Reviewed

  Annual 20073,303 words Report 1360LGenes involved in acute rejection (AR) after organ transplantation remain to be further elucidated. In a previous work we have demonstrated the under-expression of VE-Cadherin by endothelial cells (EC) in AR following...

• The effect of combination therapy with rituximab and intravenous immunoglobulin on the progression of chronic antibody mediated rejection in renal transplant recipients

  Authors:Gun Hee An, Jintak Yun, Yu Ah Hong, Marina Khvan, Byung Ha Chung, Bum Soon Choi, et al.From:Journal of Immunology Research (Vol. 2014) Peer-Reviewed

  Annual 20144,344 words Report 1400LThe treatment for chronic active antibody-mediated rejection (CAMR) remains controversial. We investigated the efficacy of rituximab (RTX) and intravenous immunoglobulin (IVIg) for CAMR. Eighteen patients with CAMR were...

• Development of Banff Classification from 1991 to 2019 for identifying renal allograft rejection: A narrative review for nephrologists.

  Authors:Murtaza Dhrolia and Aasim AhmadFrom:Journal of Pakistan Medical Association (Vol. 72, Issue 8)

  Aug. 31, 20224,033 words Report 1580LByline: Murtaza Dhrolia and Aasim Ahmad Keywords: Development, Banff classification, Renal allograft rejection. Introduction Before the Banff Classification, which in 1991 standardised the international...

• A chronic rejection model and potential biomarkers for vascularized composite allotransplantation.

  Authors:Flemming Puscz, Mehran Dadras, Alexander Dermietzel, Frank Jacobsen, Marcus Lehnhardt, Björn Behr, et al.From:PLoS ONE (Vol. 15, Issue 6) Peer-Reviewed

  June 26, 20206,545 words Report 1340LBackground Chronic rejection remains the Achilles heel in vascularized composite allotransplantation. Animal models to specifically study chronic rejection in vascularized composite allotransplantation do not exist so...

• Impact of Liver Biopsy Size on Histopathologic Evaluation of Liver Allograft Rejection.

  Authors:Apeksha N. Agarwal, Jason Nania, Lianqun Qiu, Brian Lewis, and Daniel D. MaisFrom:Archives of Pathology & Laboratory Medicine (Vol. 146, Issue 12) Peer-Reviewed

  Dec. 20223,338 words Report 1570L* Context.--Allograft liver biopsy is the gold standard in assessing transplant recipients for graft dysfunction. The impact of biopsy sample size on the diagnosis of acute cellular rejection (ACR) has not been studied....

• Clinical impact of complement (C1q, C3d) binding De Novo donor-specific HLA antibody in kidney transplant recipients.

  Authors:Hyeyoung Lee, Eunhee Han, Ae-Ran Choi, Tae Hyun Ban, Byung Ha Chung, Chul Woo Yang, et al.From:PLoS ONE (Vol. 13, Issue 11) Peer-Reviewed

  Nov. 14, 20186,676 words Article 1420LIntroduction Complement binding activity of donor-specific HLA antibodies (DSA) has been suggested as a new tool to stratify immunologic risk in kidney transplantation (KT). The objective of this study was to evaluate...

• Immunosuppression: learning from the masters

  Authors:Chris A Benedict and Edith M JanssenFrom:Expert Review of Clinical Immunology (Vol. 3, Issue 5) Peer-Reviewed

  Sept. 20072,686 words Editorial Author(s): Chris A Benedict 1 , Edith M Janssen [[dagger]] 2 Over the past 20 years, a large array of immunosuppressants has been developed to prevent and treat allograft rejection. However, the Holy Grail of...